U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H41N5O7
Molecular Weight 475.5795
Optical Activity UNSPECIFIED
Defined Stereocenters 11 / 11
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NETILMICIN

SMILES

[H][C@]3(O[C@@H]1[C@@H](N)C[C@@H](NCC)[C@H](O[C@@]2([H])OC[C@](C)(O)[C@H](NC)[C@H]2O)[C@H]1O)OC(CN)=CC[C@H]3N

InChI

InChIKey=CIDUJQMULVCIBT-MQDUPKMGSA-N
InChI=1S/C21H41N5O7/c1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)14(27)17(13)33-20-15(28)18(25-3)21(2,29)9-30-20/h5,11-20,25-29H,4,6-9,22-24H2,1-3H3/t11-,12+,13-,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H41N5O7
Molecular Weight 475.5795
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 11 / 11
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Netilmicin is a semisynthetic, water soluble antibiotic of the aminoglycoside group, produced by the fermentation of Micromonospora inyoensis, a species of actinomycete. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. It is active at low concentrations against a wide variety of pathogenic bacteria including Escherichia coli, bacteria of the Klebsiella-Enterobacter-Serratia group, Citrobacter sp., Proteus sp. (indole-positive and indole-negative), including Proteus mirabilis, P. morganii, P. rettgrei, P. vulgaris, Pseudomonas aeruginosa and Neisseria gonorrhoea. Netilmicin is also active in vitro against isolates of Hemophilus influenzae, Salmonella sp., Shigella sp. and against penicillinase and non-penicillinase-producing Staphylococcus including methicillin-resistant strains. Some strains of Providencia sp., Acinetobacter sp. and Aeromonas sp. are also sensitive to netilmicin. Many strains of the above organisms which are found to be resistant to other aminoglycosides, such as kanamycin, gentamicin, tobramycin and sisomicin, are susceptible to netilmicin in vitro. Occasionally, strains have been identified which are resistant to amikacin but susceptible to netilmicin. The combination of netilmicin and penicillin G has a synergistic bactericidal effect against most strains of Streptococcus faecalis (enterococcus). The combined effect of netilmicin and carbenicillin or ticarcillin is synergistic for many strains of Pseudomonas aeruginosa. In addition, many isolates of Serratia, which are resistant to multiple antibiotics, are inhibited by synergistic combinations of netilmicin with carbenicillin, azlocillin, mezlocillin, cefamandole, cefotaxime or moxalactam. Netilmicin "irreversibly" binds to specific 30S-subunit proteins and 16S rRNA. Specifically netilmicin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes, leaving the bacterium unable to synthesize proteins vital to its growth.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.7 mM [Ki]
0.11565 mM [IC50]
23.1 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
NETROMYCIN
Curative
Unknown

AUC

ValueDoseCo-administeredAnalytePopulation
76.9 mg × h/L
4.5 mg/kg single, intravenous
NETILMICIN serum
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
6.1 h
4.5 mg/kg single, intravenous
NETILMICIN serum
Homo sapiens

Doses

AEs

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Adult: 4-6 mg/kg once daily or in equally divided doses given every 8 or 12 hours. Life-threatening infections: Increase to up to 7.5 mg/kg daily every 8 hours. Treatment is usually given for 7-14 days. Child: Premature infants and neonates <1 week: 6 mg/kg daily in divided doses every 12 hours. Infants and neonates >1 week: 7.5-9 mg/kg daily in divided doses every 8 hours. Older children: 6-7.5 mg/kg daily in divided doses every 8 hours. Alternative regimen: Neonates <6 weeks: 4-6.5 mg/kg daily in divided doses every 12 hours. Older infants and children: 5.5-8 mg/kg daily in divided doses every 8 or 12 hours.
Route of Administration: Other
In Vitro Use Guide
MIC (Minimum inhibitory concentration) of netilmicin against P. aeruginosa in unadjusted broth was 0.73 ug/ml for gentamicin-susceptible strains and 1.35 ug/ml for gentamicin-resistant strains
Substance Class Chemical
Record UNII
4O5J85GJJB
Record Status Validated (UNII)
Record Version